4.1 Article

Design of the functional requirements of a smartphone app for patients receiving oral antineoplastic agents: The e-OncoSalud® app

Journal

JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Volume 26, Issue 1, Pages 105-115

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/1078155219840419

Keywords

e-OncoSalud; smartphone application; home monitoring; oral antineoplastic agents; mhealth

Ask authors/readers for more resources

Objective To design a mobile app based on the needs of the onco-hematological patient receiving oral antineoplastic agents. Methods A multidisciplinary working group (pharmacy-oncology-hematology) was created to design the app. The study was developed in three phases: first, we analyzed the features of patients receiving oral antineoplastic agents. We then analyzed available apps for cancer patients. Finally, we designed the app's functionalities. Results We included 51 patients with middle-advanced age (68.7 years (SD=10.7)). They were polymedicated (mean: 5.3 (SD = 2.7), with numerous drug-drug interactions and adverse effects (all patients presented adverse effects). We then analyzed 166 apps. Most apps had more than one use, the most frequent being information (39.8%) and diagnosis (38.6%). Ten apps (6%) were for registering and monitoring treatment and adverse effects. Almost half of the apps (48.8%) were developed by healthcare organizations. Finally, we designed an app (e-OncoSalud (R)) with the following functionalities: (a) agenda; (b) treatment and drug interactions checker; (c) continuous recording of self-controls (weight, blood pressure, general condition) and adverse effects. The management of the adverse effects are based on an algorithm which provides different recommendations according to the adverse effects severity; (d) patient-pharmacist messaging in real-time; (e) education. Conclusions After analysis of the main problems affecting these patients and the needs not covered by the existing apps, we designed e-OncoSalud (R). It integrates relevant information about their treatment, focused on drug interactions identification and the prevention, and management of adverse effects.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Health Care Sciences & Services

Error Detection and Cost Savings With an Image-Based Workflow Management System Connected to a Computerized Prescription Order Entry Program for Antineoplastic Compounding

Maria Belen Marzal-Alfaro, Vicente Escudero-Vilaplana, Carmen Guadalupe Rodriguez-Gonzalez, Eva Gonzalez-Haba, Aitana Calvo, Santiago Osorio, Irene Iglesias-Peinado, Ana Herranz, Maria Sanfurjo

Summary: This study aimed to analyze the prevalence of errors and associated costs with the implementation of an image-based workflow management system during the antineoplastic compounding process. Results showed that Phocus Rx system effectively prevented errors reaching patients and was cost-effective from the hospital's perspective.

JOURNAL OF PATIENT SAFETY (2021)

Article Pharmacology & Pharmacy

Novel mobile application for direct communication between pharmacists and patients treated with oral antineoplastic agents

Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Almudena Ribed, Rosa Romero Jimenez, Irene Iglesias Peinado, Ana Herranz-Alonso, Maria Sanjurjo-Saez

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2020)

Article Health Care Sciences & Services

Features and Functionalities of Smartphone Apps Related to COVID-19: Systematic Search in App Stores and Content Analysis

Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Cristina Villanueva-Bueno, Ana Herranz-Alonso, Maria Sanjurjo-Saez

JOURNAL OF MEDICAL INTERNET RESEARCH (2020)

Article Oncology

Aggressiveness of end-of-life cancer care: what happens in clinical practice?

Estela Garcia-Martin, Vicente Escudero-Vilaplana, Barbara Fox, Roberto Collado-Borrell, Belen Marzal-Alfaro, Maria Sanchez-Isac, Maria Luisa Solano-Garzon, Ricardo Gonzalez del Val, Jose Manuel Cano-Gonzalez, Nuria Perez de Lucas, Ana Isabel Bravo-Guillen, Javier Valero-Salinas, Eva Gonzalez-Haba, Maria Sanjurjo, Miguel Martin

Summary: The study found that end-of-life cancer care in the clinical practice of the hospital tended to be aggressive, with a significant proportion of patients receiving anti-cancer treatments close to death. However, the quality of care did not meet the high standards set by the Earle criteria. While more than half of the patients received hospice services before death, in some cases, this care started only shortly before the patients passed away.

SUPPORTIVE CARE IN CANCER (2021)

Article Health Care Sciences & Services

Effect of a Mobile App for the Pharmacotherapeutic Follow-Up of Patients With Cancer on Their Health Outcomes: Quasi-Experimental Study

Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Almudena Ribed, Cristina Gonzalez-Anleo, Maite Martin-Conde, Rosa Romero-Jimenez, Irene Iglesias-Peinado, Ana Herranz-Alonso, Maria Sanjurjo-Saez

JMIR MHEALTH AND UHEALTH (2020)

Article Oncology

Acute pancreatitis in a patient treated with imatinib and gefitinib

Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Cristina Villanueva-Bueno, Rosa Alvarez, Ana Herranz, Maria Sanjurjo

Summary: This case report describes a possible case of acute pancreatitis induced by the interaction between imatinib and gefitinib. The patient received supportive treatment but eventually passed away 3 months after discontinuation of the two drugs.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)

Article Oncology

Standardizing Health Outcomes for Lung Cancer. Adaptation of the International Consortium for Health Outcomes Measurement Set to the Spanish Setting

Vicente Escudero-Vilaplana, Antonio Calles, Roberto Collado-Borrell, Maria Belen Marzal-Alfaro, Carlos Polanco, Carmen Garrido, Jorge Suarez, Aurora Ortiz, Marilena Appierto, Marta Comellas, Luis Lizan

FRONTIERS IN ONCOLOGY (2020)

Article Environmental Sciences

Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: COSTECAT Study

Ana Rosa Rubio-Salvador, Vicente Escudero-Vilaplana, Jose Antonio Marcos Rodriguez, Irene Mangues-Bafalluy, Beatriz Bernardez, Carlos Garcia Collado, Roberto Collado-Borrell, Maria Dolores Alvarado Fernandez, Jose Ignacio Chacon Lopez-Muniz, Maria Yebenes Cortes, Manuel Gomez Barrera, Miguel Angel Calleja-Hernandez

Summary: Patients with lung cancer are at higher risk of developing VTE, leading to increased healthcare costs, with hospitalizations being the main drivers of cost.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)

Article Infectious Diseases

COVID-19 in hospitalised patients in Spain: a cohort study in Madrid

Carmen Guadalupe Rodriguez-Gonzalez, Esther Chamorro-de-Vega, Maricela Valerio, Miguel Angel Amor-Garcia, Francisco Tejerina, Milagros Sancho-Gonzalez, Alvaro Narrillos-Moraza, Alvaro Gimenez-Manzorro, Silvia Manrique-Rodriguez, Marina Machado, Maria Olmedo, Vicente Escudero-Vilaplana, Cristina Villanueva-Bueno, Beatriz Torroba-Sanz, Alejandra Melgarejo-Ortuno, Juan Vicente-Valor, Ana Herranz, Emilio Bouza, Patricia Munoz, Maria Sanjurjo

Summary: This study reported on 1255 adult cases receiving anti-COVID-19 treatment at a Spanish hospital in March 2020, revealing the severity of illness and the impact of treatment measures on some patients. The study found that factors such as age, underlying conditions like cardiovascular disease and diabetes, as well as certain abnormal biochemical markers, were closely associated with the risk of death.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)

Article Oncology

Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice

Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Maria del Monte-Millan, Angela Hoyo-Munoz, Patricia Gomez Martinez-Sagrera, Jose Luis Revuelta-Herrero, Belen Marzal-Alfaro, Eva Gonzalez-Haba, Sara Lopez-Tarruella Cobo, Yolanda Jerez Gilarranz, Ana Herranz, Maria Sanjurjo, Miguel Martin

Summary: The study analyzed the incidence, characteristics, and severity of diarrhea in cancer patients treated with targeted oral antineoplastic agents, identifying that more than a third of patients experienced diarrhea, and that taking the medication on an empty stomach was significantly associated with an increased risk of diarrhea.

SUPPORTIVE CARE IN CANCER (2021)

Article Oncology

Chimeric Antigen Receptor T Cell Therapy Management and Safety: A Practical Tool From a Multidisciplinary Team Perspective

Maria Belen Marzal-Alfaro, Vicente Escudero-Vilaplana, Jose Luis Revuelta-Herrero, Roberto Collado-Borrell, Ana Herranz-Alonso, Maria Sanjurjo-Saez

Summary: This study aimed to develop a structured guide to support hospital pharmacist responsibilities in CAR-T cell therapy programs in Europe. A multidisciplinary team defined key tasks and issued recommendations to improve patient safety and treatment efficacy, creating a checklist to ensure compliance with standard operating procedures. The guide provides safety recommendations for CAR-T therapy management and standardizes hospital pharmacists' responsibilities within the team.

FRONTIERS IN ONCOLOGY (2021)

Article Pharmacology & Pharmacy

Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

Cristina Villanueva-Bueno, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Alvaro Gimenez-Manzorro, Almudena Ribed, Belen Marzal-Alfaro, Jose Luis Revuelta-Herrero, Eva Gonzalez-Haba, Ana Herranz, Maria Sanjurjo

Summary: Oral antineoplastic agents (OAAs) are high-risk drugs that may increase the risk of bleeding, difficulty in wound healing, or produce alterations in coagulation and/or platelet aggregation. Most OAAs require perioperative monitoring, and only a small number have specific recommendations for temporary suspension before surgery. This review provides a comprehensive guide for healthcare professionals to manage OAAs during the perioperative process.

EXPERT OPINION ON DRUG SAFETY (2022)

Article Pharmacology & Pharmacy

Thalidomide as treatment of refractory thoracic Rosai-Dorfman disease

Angela Hoyo-Munoz, Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Mariana Bastos-Oreiro, Ana Herranz-Alonso, Maria Sanjurjo-Saez

Summary: This case report describes a 74-year-old female with pulmonary RDD who responded to thalidomide treatment after failing multiple previous therapies. Thalidomide induced remission in this refractory pulmonary RDD case, showing rapid onset of action and lasting responses, offering an exciting treatment option for this life-threatening condition.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2022)

Article Biochemistry & Molecular Biology

Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice

Juan Vicente-Valor, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Sara Perez-Ramirez, Cristina Villanueva-Bueno, Alvaro Narrillos-Moraza, Sebastian Garcia-Sanchez, Manel Beamud-Cortes, Ana Herranz, Maria Sanjurjo

Summary: Abiraterone and enzalutamide, ARPIs for mCRPC, have high risk of PDIs. This study found that at least two-thirds of patients treated with ARPIs experienced PDIs, with polypharmacy and treatment with enzalutamide associated with higher risk.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2021)

Article Oncology

Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients

Juan Vicente-Valor, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Cristina Lopez-Lopez, Cristina Villanueva-Bueno, Jose Luis Revuelta-Herrero, Paula Ruiz-Briones, Beatriz Somoza-Fernandez, Ana Herranz, Maria Sanjurjo

Summary: The combination of spironolactone with abiraterone in patients with mCRPC may compromise the therapeutic effectiveness of abiraterone due to potential androgenic effects of spironolactone. Despite the potential benefits for cardiac conditions, combining spironolactone with abiraterone may lead to disease progression, as evidenced by rising PSA levels and tumor progression observed in two cases discussed. Strategies to address this interaction could involve alternative medications such as eplerenone, with a multidisciplinary approach recommended for evaluation by cardiologists and oncologists.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2022)

No Data Available